Identification of β-glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma is associated with resistance to chemotherapy drugs. (2nd April 2016)

• Record Type: Journal Article
• Authors: Zhang, Ye; Zhu, Kuiyu; Miao, Xiaofei; Hu, Xingqian; Wang, Tong
• Is Part Of: Biomarkers. Volume 21:Number 3(2016)
• Page Start: 249
• Page End: 256
• Publication Date: 2016-04-02
• Subjects: Biomarker -- hepatocellular carcinoma -- β-glucosidase -- targeted therapy; Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2015.1134662
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Context and objective : Long-term prognosis of hepatocellular carcinoma (HCC) patients is challenging, and novel biomarkers are needed to predict patient risk and serve as potential therapeutic target. Results : We found β-glucosidase 1 is significantly overexpressed and activated in primary HCC tissue and multiple HCC cell lines. β-Glucosidase 1 expression is associated with predicting prognosis of HCC patients under chemotherapy. Silencing β-glucosidase 1 inhibits growth and survival of HCC cells, with preferential inhibitory effects on high β-glucosidase 1-expressing cells. Combination of chemo drug with β-glucosidase 1 inhibitor sensitized HCC cells to chemotherapy. Conclusion : Our data support β-glucosidase 1 as a HCC biomarker due to its prognosis significance.